Lessons From Liquidia: Designing Precision Drugs to Transform Pharma
With Shawn Glidden, Vice President of Legal Affairs and Secretary, Liquidia Technologies, Inc.

Imagine if you could engineer drug particles with extreme precision – at practically any shape, size or composition – to get the best therapeutic results for patients. Where would you initially apply the technology? But wait – first you need to scale manufacturing capabilities and fund research, development and clinical studies. Join us at the next Carolina Innovations Seminar, where you’ll hear how this vision is being made possible by UNC-Chapel Hill spinout company Liquidia Technologies. Shawn Glidden, Vice President of Legal Affairs and Secretary of Liquidia, will join us to share an insider’s perspective on the company and how he helped take the firm from a newly formed private entity through its recent NASDAQ public offering, which closed with $53 million in gross proceeds.Learn how Mr. Glidden helped build the initial concept for Liquidia into a public company with a product candidate in phase 3 clinical trials. During his talk, he’ll share experiences and lessons learned while:

• Raising multiple rounds of private venture capital and NASDAQ IPO
• Negotiating licensing agreements across a technology platform without getting entangled
• Advancing a novel manufacturing technology to commercial scale
• Building patent and trade secret protection around a manufacturing technology and product platform
• Maturing a private company into a compliant pre-commercial public biotech

Register now